{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:09Z","timestamp":1790689749400,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T00:00:00Z","timestamp":1303257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0019037","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T21:01:48Z","timestamp":1303333308000},"page":"e19037","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":56,"title":["Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse"],"prefix":"10.1371","volume":"6","author":[{"given":"Ying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Zamzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Bielawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Kitatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D. R.","family":"Setchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf A.","family":"Hannun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,20]]},"reference":[{"key":"ref1","article-title":"Gaucher disease.","author":"GA Grabowski","year":"2010"},{"key":"ref2","article-title":"Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity.","author":"N Gupta","year":"2010"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.","volume":"113","author":"NJ Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.","volume":"22","author":"RJ Wenstrup","year":"2007","journal-title":"J Bone Miner Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1.","volume":"11","author":"GA Grabowski","year":"2009","journal-title":"Genet Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2006.10.062","article-title":"Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.","volume":"150","author":"TA Burrow","year":"2007","journal-title":"J Pediatr"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02815346","article-title":"Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase.","volume":"21","author":"NS Radin","year":"1994","journal-title":"Mol Chem Neuropathol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.20504","article-title":"Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.","volume":"80","author":"NJ Weinreb","year":"2005","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.","volume":"91","author":"KA McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.","volume":"33","author":"J Marshall","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.","volume":"116","author":"E Lukina","year":"2010","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/BC.2008.009","article-title":"A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.","volume":"389","author":"JQ Fan","year":"2008","journal-title":"Biol Chem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.","volume":"99","author":"AR Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1371\/journal.pbio.0060026","article-title":"Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.","volume":"6","author":"TW Mu","year":"2008","journal-title":"PLoS Biol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.","volume":"103","author":"RA Steet","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.","author":"R Khanna","year":"2010"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.","volume":"19","author":"Y Sun","year":"2010","journal-title":"Hum Mol Genet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tips.2007.04.008","article-title":"Novel strategies for inhibition of the p38 MAPK pathway.","volume":"28","author":"J Zhang","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"12979","DOI":"10.1074\/jbc.M809500200","article-title":"Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid.","volume":"284","author":"K Kitatani","year":"2009","journal-title":"J Biol Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.","volume":"3","author":"RL Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.","volume":"48","author":"RL Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","article-title":"Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.","volume":"5","author":"YH Xu","year":"2010","journal-title":"PLoS One"},{"key":"ref23","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.","author":"YH Xu","year":"2008"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.","volume":"163","author":"YH Xu","year":"2003","journal-title":"Am J Pathol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"31918","DOI":"10.1074\/jbc.M302752200","article-title":"Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation.","volume":"278","author":"Y Sun","year":"2003","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/hmg\/ddp531","article-title":"Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse.","volume":"19","author":"Y Sun","year":"2010","journal-title":"Hum Mol Genet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","article-title":"Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.","volume":"126","author":"M Jeyakumar","year":"2003","journal-title":"Brain"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ana.20242","article-title":"NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.","volume":"56","author":"M Jeyakumar","year":"2004","journal-title":"Ann Neurol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nbd.2009.07.010","article-title":"Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1.","volume":"36","author":"D Smith","year":"2009","journal-title":"Neurobiol Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainres.2009.09.017","article-title":"Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy.","volume":"1300","author":"P Luzi","year":"2009","journal-title":"Brain Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-4-21","article-title":"A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.","volume":"4","author":"L Munoz","year":"2007","journal-title":"J Neuroinflammation"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neurobiolaging.2006.11.013","article-title":"Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia.","volume":"29","author":"A Klegeris","year":"2008","journal-title":"Neurobiol Aging"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.","volume":"15","author":"TD Butters","year":"2005","journal-title":"Glycobiology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ja.2009.53","article-title":"Gem-diamine 1-N-iminosugars as versatile glycomimetics: synthesis, biological activity and therapeutic potential.","volume":"62","author":"Y Nishimura","year":"2009","journal-title":"J Antibiot (Tokyo)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1095336","article-title":"Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation.","volume":"304","author":"Z Zhu","year":"2004","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1194\/jlr.M500202-JLR200","article-title":"Gaucher disease mouse models: point mutations at the acid {beta}-glucosidase locus combined with low-level prosaposin expression lead to disease variants.","volume":"46","author":"Y Sun","year":"2005","journal-title":"J Lipid Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"12972","DOI":"10.1074\/jbc.M802790200","article-title":"Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation.","volume":"284","author":"K Kitatani","year":"2009","journal-title":"J Biol Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1203\/00006450-199602000-00021","article-title":"Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues.","volume":"39","author":"YH Xu","year":"1996","journal-title":"Pediatr Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/hmg\/ddn135","article-title":"Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice.","volume":"17","author":"Y Sun","year":"2008","journal-title":"Hum Mol Genet"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0019037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T02:55:43Z","timestamp":1540263343000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0019037"}},"subtitle":[],"editor":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,20]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0019037","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,20]]}}}